Evidence map›Paper›PMID 27506940›Full record

ArticleOncotarget2016

Aberrant DR5 transport through disruption of lysosomal function suggests a novel mechanism for receptor activation.

Birce Akpinar, Barbora Safarikova, Jarmila Laukova, Shubhranshu Debnath, Alena Hyrslova Vaculova, Boris Zhivotovsky, Magnus Olsson

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Birce AkpinarDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Barbora SafarikovaDepartment of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
Jarmila LaukovaDepartment of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
Shubhranshu DebnathDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Alena Hyrslova VaculovaDepartment of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, v.v.i., Brno, Czech Republic.
Boris ZhivotovskyDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Magnus OlssonDivision of Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SECzech Academy of Sciences · CZCzech Academy of Sciences, Institute of Biophysics · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To examine reciprocal or unilateral implications between two cell destruction processes, autophagy and apoptosis, in 5-Fluorouracil (5-FU)-treated tumor cells, a combination of chemical inhibitors, RNAi and genetic approaches were used. In contrast to cancer cells harboring obstructed apoptosis, either at the DISC or the mitochondrial level, p53-deficiency generated signs of autophagy deregulation upon chemotherapy. On the other, hand disruption of lysosomal function by chloroquine, caused a profound decrease in apoptotic markers appearing in response to 5-FU. DR5, which is essential for 5-FU-induced apoptosis, accumulated in lysosomes and autophagosomes upon chloroquine treatment. Since neither 3-MA, RNAi of critical autophagy regulators or inhibition of cathepsins reversed apoptosis in a similar manner, it is likely that not autophagy per se but rather correct receptor transport is an important factor for 5-FU cytotoxicity. We found that apoptosis generated by TRAIL, the cognate ligand for DR5, remained unchanged upon chloroquine lysosomal interference, indicating that 5-FU activates the receptor by a discrete mechanism. In support, depletion of membrane cholesterol or hampering cholesterol transport drastically reduced 5-FU cytotoxicity. We conclude that targeting of lysosomes by chloroquine deregulates DR5 trafficking and abrogates 5-FU- but not TRAIL-stimulated cell elimination, hence suggesting a novel mechanism for receptor activation.

Indexed as

AutophagyAntimetabolites, AntineoplasticApoptosisCell MembraneChloroquineCholesterolFluorouracilHCT116 CellsHumansLigandsLysosomesMacrolidesMitochondriaPhagosomesProtein TransportReceptors, TNF-Related Apoptosis-Inducing LigandAntimetabolites, Antineoplasticbafilomycin AChloroquineCholesterolFluorouracilLigandsMacrolidesReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFRSF10B protein, humanTP53 protein, humanTumor Suppressor Protein p53apoptosisautophagychloroquineDR5lysosomes

Identifiers

PMID27506940
PMCPMC5295431
OpenAlexW2500935108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.